Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 1;20(4):409-415.
doi: 10.1097/COH.0000000000000948. Epub 2025 May 13.

Balancing polypharmacy and comorbidity management: cardiovascular health

Alex E Rock  1   2 , Matthew L Russell  3 , Virginia A Triant  2   4
Affiliations
Review

Balancing polypharmacy and comorbidity management: cardiovascular health

Alex E Rock et al. Curr Opin HIV AIDS. .

Abstract

Purpose of review: This review will discuss statin therapy for prevention of cardiovascular disease (CVD) among people with HIV (PWH) in the context of balancing prevention and treatment of chronic diseases with challenges related to polypharmacy.

Recent findings: Aging PWH confront an increased risk of chronic diseases, resulting in the need for prevention and treatment of comorbidities in addition to antiretroviral therapy (ART). Paradigm-shifting data from the REPRIEVE trial demonstrated a reduction in CVD events with statin therapy among PWH at low to moderate CVD risk, prompting the Department of Health and Human Services (HHS) to recommend statin therapy for primary prevention of CVD in people with HIV aged 40-75 years. Statins should be initiated according to guideline recommendations for CVD prevention, and discussion of statin initiation should include consideration of concurrent medications and the potential effects of polypharmacy.

Summary: Statins should be initiated for primary prevention of CVD in people with HIV age 40-75 years. The effects of polypharmacy should be considered in all aging PWH. Prevention and treatment of chronic diseases among PWH is important to reduce morbidity and mortality and promote healthy aging.

Keywords: HIV; aging; cardiovascular; polypharmacy; statin.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none

Similar articles

See all similar articles

References

    1. Russell ML, Justice A. Human Immunodeficiency Virus in Older Adults. Clin Geriatr Med. 2024;40(2):285–298.

      This review provides an overview of the epidemiology and management of chronic diseases and geriatric syndromes in older people with HIV and includes a section on polypharmacy.

    1. Yang C, Teh YE, Chua NGS, Lee KLS, Ng RQM. An overview of multimorbidity and polypharmacy in older people living with HIV. Geriatr Gerontol Int. 2024;24 Suppl 1:49–59. - PubMed
    1. Sheets K, Baker JV. HIV and Inflamm-Aging: How Do We Reach the Summit of Healthy Aging? Top Antivir Med. 2024;32(5):589–596. - PMC - PubMed
    1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533. - PMC - PubMed
    1. Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV Cohort Study. Clin Infect Dis. 2014. - PubMed

Substances